NCT01231659View on ClinicalTrials.gov

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 9, 2011

Primary Completion Date

November 20, 2012

Study Completion Date

April 30, 2017

Conditions
Postmenopausal WomenLocally Advanced Metastatic Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Everolimus

Everolimus 10 mg (2 tablets of 5 mg) once daily

DRUG

Letrozole

Letrozole 2.5 mg once daily

Trial Locations (7)

49100

Novartis Investigative Site, Petah Tikva

52621

Novartis Investigative Site, Ramat Gan

62439

Novartis Investigative Site, Tel Aviv

76100

Novartis Investigative Site, Rehovot

91120

Novartis Investigative Site, Jerusalem

4428164

Novartis Investigative Site, Kfar Saba

6423906

Novartis Investigative Site, Tel Aviv

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY